Standalone and Consolidated Financial Results for Q2 and half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Makers Laboratories reported a strong Q2 FY26 turnaround on both standalone and consolidated bases. Standalone Q2 revenue grew about 35% YoY to ₹1,372.68 lakhs (vs ₹1,018.83 lakhs), with PAT swinging from a loss of ₹140.48 lakhs to a profit of ₹93.98 lakhs. Consolidated Q2 PAT attributable to owners jumped roughly 172% YoY to ₹203.31 lakhs on revenue of around ₹2,956.80 lakhs. For H1 FY26, consolidated PAT grew about 20% to ₹1,090.75 lakhs, while standalone PAT declined to ₹371.54 lakhs from ₹681.38 lakhs a year ago. The Pharmaceutical segment remains the main profit driver (PBT of ₹1,341.06 lakhs in H1), but the Chemical Manufacturing segment continues to bleed, with H1 PBT loss widening to ₹250.31 lakhs from ₹156.50 lakhs. Auditors N V C & Associates LLP issued an unmodified limited review report on the results.
Positive for sentiment given the sharp Q2 profit recovery and strong revenue growth, but standalone H1 PAT decline, widening losses in the Chemical Manufacturing segment, and negative standalone operating cash flow (–₹370.94 lakhs in H1) temper the enthusiasm. Mixed signals for shareholders in the near term.